Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Nov 27, 2026; 18(11): 124292
Published online Nov 27, 2026. doi: 10.4240/wjgs.124292
Published online Nov 27, 2026. doi: 10.4240/wjgs.124292
Impact of perioperative Helicobacter pylori eradication therapy on long-term survival after distal gastrectomy for gastric cancer
Rui-Chun Shi, Dan Jin, Dan Su, Xiao-Ting Yang, Xin Wang, Jin-Fang Hao, Department of Gastroenterology, Wuzhong People’s Hospital, Wuzhong 751100, Ningxia Hui Autonomous Region, China
Zhi-Wei Yang, Department of Hematology and Rheumatology, Wuzhong People’s Hospital, Wuzhong 751100, Ningxia Hui Autonomous Region, China
Co-first authors: Rui-Chun Shi and Dan Jin.
Author contributions: Shi RC and Jin D are the co-first authors of this study and have made equal contributions, including study design, data collection and analysis, and manuscript preparation; Su D, Yang XT, Wang X, and Hao JF designed the experiments and conducted clinical data collection, performed postoperative follow-up and recorded the data; Shi RC, Jin D, and Yang ZW collated the data and performed statistical analysis, wrote the original manuscript and revised the paper; all authors read and approved the final manuscript.
AI contribution statement: No AI tools were used in writing, editing, or generating any part of this manuscript, including text, images, and data analysis.
Supported by National Health Capacity Building and Continuing Education Center 2025 Chronic Disease Management Research Project, No. GWJJMB202510025121.
Institutional review board statement: This study was approved by the Ethics Committee of Wuzhong People’s Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
Corresponding author: Zhi-Wei Yang, Department of Hematology and Rheumatology, Wuzhong People’s Hospital, No. 143 Xinmin Road, Litong District, Wuzhong 751100, Ningxia Hui Autonomous Region, China. 13909531360@163.com
Received: June 18, 2026
Revised: July 23, 2026
Accepted: September 18, 2026
Published online: November 27, 2026
Processing time: 146 Days and 19.7 Hours
Revised: July 23, 2026
Accepted: September 18, 2026
Published online: November 27, 2026
Processing time: 146 Days and 19.7 Hours
Core Tip
Core Tip: This retrospective cohort study evaluated whether perioperative Helicobacter pylori (H. pylori) eradication therapy is associated with improved long-term outcomes in H. pylori-positive patients after distal gastrectomy for gastric cancer. Eradication therapy was independently associated with higher 5-year overall survival and disease-free survival, lower metachronous gastric cancer risk, better nutritional recovery, less advanced remnant gastric atrophy, and improved chemotherapy tolerance. These findings suggest that perioperative H. pylori eradication may be a valuable adjunct to comprehensive postoperative management.